BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:

• The randomized phase III FLAIR trial
• The randomized phase III SEQUOIA trial
• The randomized phase III BRUIN CLL-321 trial
   

Presenters:

James Davis, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
MUSC Hollings Cancer Center
Assistant Professor
MUSC College of Pharmacy
Charleston, South Carolina

Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Link to full program: 
https://bit.ly/3H2EcSX

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.